Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Casopitant plus ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting during moderately emetogenic chemotherapy
2006-000781-37Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of casopitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by GSK. Primary endpoint: Complete response over 120 hours after first chemotherapy cycle. Started Apr 2006; status: completed.
02
Drugs
casopitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2006-000781-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000781-37.